Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats

Pharmacological Reports

Volumn 60, Issue 4, 2008, Pages 532-541

  Al Salami, Hani ^a   Butt, Grant ^b   Tucker, Ian ^a   Mikov, Momir ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Bile acid; Diabetes; Glibenclamide; Glielazide; Permeation; Rifampicin; Transporters; Verapamil

Indexed keywords

12 MONOKETOCHOLIC ACID; ALLOXAN; BILE ACID; DRUG CARRIER; GLIBENCLAMIDE; GLICLAZIDE; MULTIDRUG RESISTANCE PROTEIN 3; RIFAMPICIN; UNCLASSIFIED DRUG; VERAPAMIL;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MIXTURE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ILEUM; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEMBRANE TRANSPORT; MONOTHERAPY; NONHUMAN; RAT; WISTAR RAT;

EID: 52049107436     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Alam M, Rahman, M: Changes in the saccharoid fraction in rats with alloxan-induced diabetes or injected with epinephrine. Clin Chem, 1971, 17, 915-920.
2. Bachmann K, Pardoe D, White D: Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect, 1996, 104, 400-407.
3. Barbeau W, Bassaganya-Riera J, Hontecillas R: Putting the pieces of the puzzle together - a series of hypotheses on the etiology and pathogenesis of type 1 diabetes. Med Hypotheses, 2007, 68, 607-619.
4. Boisset M, Botham R, Haegele K, Lenfant B, Pachot J: Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: importance of drug ionisation in the in vitro prediction of in vivo absorption. Eur J Pharm Sci, 2000, 10, 215-224.
5. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst, 2000, 92, 1295-1302.
6. Butler A, Janson J, Bonner-Weir S, Ritzel R, Rizza R, Butler P: β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes, 2003, 52, 102-110.
7. Butt A, Mathieson S, McLeod B. Electrogenic ion transport in the intestine of the Australian common brushtail possum, Trichosurus vulpecula: indications of novel transport patterns in a marsupial. J Comp Physiol, 2002, 172, 495-502.
8. Campbell D, Lavielle R, Nathan C: The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract, 1991, 14, Suppl 2, S21-36.
9. Carvalho EN de, Carvalho NAS de, Ferreira LM: Experimental model of induction of diabetes mellitus in rats. Acta Cir Bras, 2003, 18, 60-64.
10. Chan L, Lowes S, Hirst B: The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci, 2004, 21, 25-51.
11. Chanteux H, Van Bambeke, Mingeot-Leclercq M, Tulkens P: Accumulation and oriented transport of ampicillin in Caco-2 cells from its pivaloyloxymethylester prodrug, pivampicillin. Antimicrob Agents Chemother, 2005, 49, 1279-1288.
12. Choudhuri S, Klaassen C: Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol, 2006, 25, 231-259.
13. Cvetkovic M, Leake B, Fromm M, Wilkinson G, Kim R: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos, 1999, 27, 866-871.
14. Delrat P, Paraire M, Jochemsen R: Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. Biopharm Drug Dispos, 2002, 23, 151-157.
15. Dietrich C, Geier A, Oude Elferink R: ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut, 2003, 52, 1788-1795.
16. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC et al.: Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest, 1998, 101, 1310-1319.
17. Fromm M, Kauffamnn H, Fritz P, Burk O, Kroemer H, Warzok R: The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol, 2000, 157, 1575-1580.
18. Fromm M, Kauffmann H, Fritz P, Burk O, Kroemer H, Warzok R, Eichelbaum M et al.: The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol, 2000, 157, 1575-1580.
19. Garcia-Bournissen F, Feig D, Koren G: Maternal-fetal transport of hypoglycaemic drugs. Clin Pharmacokinet, 2003, 42, 303-313.
20. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta, 2006, 27, 1096-1102.
21. Golstein P, Boom A, Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Eur J Physiol, 1999, 437, 652-660.
22. Gordon G, Moses A, Silver R, Flier J, Carey M: Nasal absorption of insulin: enhancement by hydrophobic bile salts. Proc Natl Acad Sci USA, 1985, 82, 7419-7423.
23. Hirohashi T, Suzuki H, Sugiyama Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem, 1999, 274, 15181-15185.
24. Huang Y, Sadee W: Membrane transporters and channels in chemoresistance and sensitivity of tumor cells. Cancer Lett, 2005, 239, 168-182.
25. Hunter J, Hirst B: Intestinal secretiorf of drugs. The role of P-glycoprotrin and related drug efflux systems in limiting oral drug absorption. Adv Drug Del Rev, 1997, 25, 129-157.
26. Ito K, Suzuki H, Horie T, Sugiyama Y: Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res, 2005, 22, 1559-1577.
27. Khavinson V: Effect of tetrapeptide on insulin biosynthesis in rats with alloxan-induced diabetes. Bull Exp Biol Med, 2005, 140, 452-454.
28. Korec R: Treatment of alloxan and streptozotocin diabetes in rats by intrafamiliar homo (allo) transplantation of neonatal pancreases. Endocrinol Exp, 1980, 14, 191-198.
29. Kuhajda K, Kandrac J, Kevresan S, Mikov M, Fawcett J: Structure and origin of bile acids: an overview. Eur J Drug Metab Pharmacokinet, 2006, 31, 135-143.
30. Kuhajda K, Kevresan S, Kandrac J, Fawcett J, Mikov M: Chemical and metabolic transformations of selected bile acids. Eur J Drug Metab Pharmacokinet, 2006, 31, 179-235.
31. Li J, Hidalgo I: Molecular modeling study of structural requirements for the oligopeptide transporter. J Drug Target, 1996, 4, 9-17.
32. Lucas M: Amendments to the theory underlying Ussing chamber data of chloride ion secretion after bacterial enterotoxin exposure. J Theor Biol, 2005, 234, 21-37.
33. Merlob P, Levitt O, Stahl B: Oral antihyperglycemic agents during pregnancy and lactation: a review. Paediatr Drugs, 2002, 4, 755-760.
34. Mesiha MS, Ponnapula S, Plakogiannis F: Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and α-tocopherol dispersions. Int J Pharm, 2002, 249, 1-5.
35. Mikov M, Boni N, Al-Salami H, Kuhajda K, Kevresan S, Golocorbin-Kon S, Fawcett J: Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3α,7α-dihydroxy-12-oxo-5β-cholanate, in healthy and diabetic rats. Eur J Drug Metab Pharmacokinet, 2007, 32, 7-12.
36. Mikov M, Fawcett J: Chemistry, biosynthesis, analysis, chemical and metabolic transformations and pharmacology. Eur J Drug Metab Pharmacokinet, 2006, 31, 133-134.
37. Mikov M, Kevresan S, Kuhajda K, Jakovljevic V, Vasovic V: 3α,7α-Dihydroxy-12-oxo-5β-cholanate as blood-brain barrier permeator. Pol J Pharmacol, 2004, 56, 367-371.
38. Mikov M, Raskovic A, Jakovljevic E, Dudvarski D, Fawcett J: Influence of the bile salt sodium 3α,7α-dihydroxy-12-oxo-5β-cholanate on ampicillin pharmacokinetics in rats. Asian J Drug Metab Pharmacokinet, 2005, 5, 197-200.
39. Miljkovic D: Selective C-12 oxidation of cholic acid. Chem Res, 1996, 2, 106-107.
40. +/taurocholate co-transporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11) - expressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos, 2006, 34, 1575-1581.
41. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann A, Sugiyama Y: Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep. Am J Physiol Gastrointest Liver Physiol, 2006, 290, 550-556.
42. Mrestani Y, Marestani Z, Neubert R: The effect of a functional group in penicillin derivatives on the interaction with bile salt micelles studied by micellar electrokinetic chromatography. Electrophoresis, 2001, 22, 3573-3577.
43. Neu J, Reverte CM, Mackey AD, Liboni K, Tuchacek-Tenace M, Hatch M, Li N et al.: Changes in intestinal morphology and permeability in the biobreeding rat before the onset of type 1 diabetes. J Pediatr Gastroenterol Nutr, 2005, 40, 589-595.
44. Pang K: Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos, 2003, 31, 1507-1519.
45. Park J, Kim K, Kim S, Park P: Quantification of gliclazide by semi-micro high-performance liquid chromatography: application to a bioequivalence study of two formulations in healthy subjects. J Pharm Biomed Anal, 2004, 35, 943-949.
46. Pauli-Megnus M, Meier P: Hepatobiliary transporters and drug-induced cholestasis. Hepatology, 2006, 44, 778-787.
47. Rendall M: The role of sulphoylureas in the management of type2 diabetes mellitus. Drugs, 2004, 64, 1399-1358.
48. Rieutord A, Stupans I, Shenfield G, Gross A: Gliclazide hydroxylation by rat liver microsomes. Xenobiotica, 1995, 25, 1345-1354.
49. Rouini M, Mohajer A, Tahami M: A simple and sensitive HPLC method for determination of gliclazide in human serum. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 785, 383-386.
50. Sakamoto S, Suzuki H, Kusuhara H, Sugiyama Y: Efflux mechanism of taurocholate across the rat intestinal basolateral membrane. Mol Pharm, 2006, 3, 275-281.
51. Sauna Z, Smith M, Milller M, Kerr K, Ambudkar S: The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr, 2001, 33, 481-491.
52. Scheffer G, Kool M, Heijn M, de Haas M, Pijnenborg A, Wijnholds J, van Helvoort A et al.: Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res, 2000, 60, 5269-5277.
53. Schernthaner G: Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metab Clin Exp, 2003, 52, Suppl 1, 29-34.
54. Seelig A: A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem, 1998, 251, 252-261.
55. Shiau M, Tsai S, Tsai K, Haung M, Hsu Y, Chang Y: Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus. Mt Sinai J Med, 2006, 73, 1024-1028.
56. Smith RJ: Effects of the sulfonylureas on muscle glucose homeostasis. Am J Med, 1990, 89, Suppl 2A, 38S-43S.
57. St-Pierre M, Kullak-Ublick G, Hagenbuch B, Meier P: Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol, 2001, 1673-1686.
58. Werle M, Hoffer M: Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release, 2606, 111, 41-46.
59. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P et al.: Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/ drug interaction. Clin Pharmacol Ther, 2000, 68, 345-355.
60. Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu N: Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol, 2004, 18, 619-621.
61. Zelcer N, Huisman M, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P et al.: Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). Biol Chem, 2003, 278, 23538-23544.
62. Zelcer N, Saeki T, Bot I, Kuil A, Borst P: Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA, 2005, 102, 7274-7279.
63. Zollner G, Marschall H, Wagner M, Trauner M: Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm, 2006, 3, 231-251.